Prolium Bioscience

Prolium Bioscience is a clinical-stage company developing PRO-203, a potential best-in-class bispecific CD20xCD3 antibody for systemic sclerosis and other severe autoimmune diseases. Prolium was founded and supported by RTW Investments and has assembled an experienced team in the development of therapeutic drugs for autoimmune diseases.